NAUT

Over the past six months, Nautilus Biotechnology, Inc.'s stock price has increased significantly. Key events include reporting First Quarter 2026 Financial Results with a narrower net loss, participation in the Investor Summit Group Virtual Conference, and the announcement of Baylor College of Medicine as the first Early Access Program customer for its Voyager Platform. Amber Faust was appointed as Vice President of Sales, and the company reported its Fourth Quarter and Fiscal Year 2025 Financial Results. Goldman Sachs downgraded NAUT to Sell, citing skepticism about the company's ability to meet its commercialization timeline, while CEO Sujal M. Patel bought 25,000 shares.